Search Browse Earnings

Apellis Pharmaceuticals, Inc. — SlamSEC

Apellis Pharmaceuticals, Inc.

Nasdaq:APLS

Pharmaceutical Preparations·WALTHAM, MA

Overview All Filings Sum Fin Credit Insiders Governance

Overview All Filings Sum Fin Credit Insiders Governance

Summary Financials

Revenue

$396.6M

+425.8% YoY

FY 2025

Adj. EBITDA

-$515.3M

-129.9% margin

FY 2025

Net Income

-$528.6M

-133.3% margin

FY 2025

EPS (Diluted)

-$4.45

FY 2025

Stock Price

$19.97

-0.9%

2026-03-09

52W Range

$16.10 – $30.48

P/E Ratio

-4.5x

Market Cap

$2.6B

Cash

$351.2M

FY 2025

Total Debt

$93.0M

FY 2023

Net Cash

$258.2M

FY 2023

Enterprise Value

$2.3B

Debt / EBITDA

0.5x

FY 2025

EV / EBITDA

-4.5x

Employees

—

CEO

Francois Cedric